Beverages - Alcoholic
Compare Stocks
2 / 10Stock Comparison
IBG vs CRBP
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
IBG vs CRBP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Beverages - Alcoholic | Biotechnology |
| Market Cap | $1M | $136M |
| Revenue (TTM) | $8M | $0.00 |
| Net Income (TTM) | $-6M | $-79M |
| Gross Margin | 11.3% | — |
| Operating Margin | -71.3% | — |
| Total Debt | $184K | $2M |
| Cash & Equiv. | $620K | $28M |
IBG vs CRBP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 24 | May 26 | Return |
|---|---|---|---|
| Innovation Beverage… (IBG) | 100 | 1.7 | -98.3% |
| Corbus Pharmaceutic… (CRBP) | 100 | 52.7 | -47.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IBG vs CRBP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
IBG is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.13
- Rev growth -6.9%, EPS growth -16.5%, 3Y rev CAGR -7.9%
- Lower volatility, beta 1.13, Low D/E 7.0%, current ratio 1.14x
CRBP carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -85.4% 10Y total return vs IBG's -98.8%
- 3.3% margin vs IBG's -80.0%
- +77.3% vs IBG's -95.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -6.9% revenue growth vs CRBP's -98.4% | |
| Quality / Margins | 3.3% margin vs IBG's -80.0% | |
| Stability / Safety | Beta 1.13 vs CRBP's 1.36 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +77.3% vs IBG's -95.8% | |
| Efficiency (ROA) | -57.9% ROA vs IBG's -124.5%, ROIC -51.4% vs -87.3% |
IBG vs CRBP — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
IBG leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
IBG and CRBP operate at a comparable scale, with $8M and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $8M | $0 |
| EBITDAEarnings before interest/tax | -$5M | -$84M |
| Net IncomeAfter-tax profit | -$6M | -$79M |
| Free Cash FlowCash after capex | -$3M | -$64M |
| Gross MarginGross profit ÷ Revenue | +11.3% | — |
| Operating MarginEBIT ÷ Revenue | -71.3% | — |
| Net MarginNet income ÷ Revenue | -80.0% | — |
| FCF MarginFCF ÷ Revenue | -37.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -38.6% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +39.3% | -60.3% |
Valuation Metrics
Evenly matched — IBG and CRBP each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $1M | $136M |
| Enterprise ValueMkt cap + debt − cash | $966,549 | $109M |
| Trailing P/EPrice ÷ TTM EPS | -0.54x | -1.84x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.48x | — |
| Price / BookPrice ÷ Book value/share | 0.54x | 0.98x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
CRBP leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
CRBP delivers a -65.8% return on equity — every $100 of shareholder capital generates $-66 in annual profit, vs $-10 for IBG. CRBP carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to IBG's 0.07x. On the Piotroski fundamental quality scale (0–9), IBG scores 3/9 vs CRBP's 2/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -10.1% | -65.8% |
| ROA (TTM)Return on assets | -124.5% | -57.9% |
| ROICReturn on invested capital | -87.3% | -51.4% |
| ROCEReturn on capital employed | -155.2% | -58.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.07x | 0.01x |
| Net DebtTotal debt minus cash | -$435,590 | -$27M |
| Cash & Equiv.Liquid assets | $619,944 | $28M |
| Total DebtShort + long-term debt | $184,354 | $2M |
| Interest CoverageEBIT ÷ Interest expense | -13.53x | — |
Total Returns (Dividends Reinvested)
CRBP leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CRBP five years ago would be worth $2,196 today (with dividends reinvested), compared to $116 for IBG. Over the past 12 months, CRBP leads with a +77.3% total return vs IBG's -95.8%. The 3-year compound annual growth rate (CAGR) favors CRBP at 2.4% vs IBG's -77.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -91.1% | +38.1% |
| 1-Year ReturnPast 12 months | -95.8% | +77.3% |
| 3-Year ReturnCumulative with dividends | -98.8% | +7.3% |
| 5-Year ReturnCumulative with dividends | -98.8% | -78.0% |
| 10-Year ReturnCumulative with dividends | -98.8% | -85.4% |
| CAGR (3Y)Annualised 3-year return | -77.4% | +2.4% |
Risk & Volatility
Evenly matched — IBG and CRBP each lead in 1 of 2 comparable metrics.
Risk & Volatility
IBG is the less volatile stock with a 1.13 beta — it tends to amplify market swings less than CRBP's 1.36 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CRBP currently trades 52.9% from its 52-week high vs IBG's 2.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.13x | 1.36x |
| 52-Week HighHighest price in past year | $36.50 | $20.56 |
| 52-Week LowLowest price in past year | $0.84 | $6.10 |
| % of 52W HighCurrent price vs 52-week peak | +2.3% | +52.9% |
| RSI (14)Momentum oscillator 0–100 | 33.8 | 65.3 |
| Avg Volume (50D)Average daily shares traded | 790K | 262K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $51.14 |
| # AnalystsCovering analysts | — | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
CRBP leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). IBG leads in 1 (Income & Cash Flow). 2 tied.
IBG vs CRBP: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is IBG or CRBP a better buy right now?
Analysts rate Corbus Pharmaceuticals Holdings, Inc.
(CRBP) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IBG or CRBP?
Over the past 5 years, Corbus Pharmaceuticals Holdings, Inc.
(CRBP) delivered a total return of -78. 0%, compared to -98. 8% for Innovation Beverage Group Limited (IBG). Over 10 years, the gap is even starker: CRBP returned -85. 4% versus IBG's -98. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IBG or CRBP?
By beta (market sensitivity over 5 years), Innovation Beverage Group Limited (IBG) is the lower-risk stock at 1.
13β versus Corbus Pharmaceuticals Holdings, Inc. 's 1. 36β — meaning CRBP is approximately 20% more volatile than IBG relative to the S&P 500. On balance sheet safety, Corbus Pharmaceuticals Holdings, Inc. (CRBP) carries a lower debt/equity ratio of 1% versus 7% for Innovation Beverage Group Limited — giving it more financial flexibility in a downturn.
04Which is growing faster — IBG or CRBP?
On earnings-per-share growth, the picture is similar: Innovation Beverage Group Limited grew EPS -16.
5% year-over-year, compared to -60. 3% for Corbus Pharmaceuticals Holdings, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — IBG or CRBP?
Corbus Pharmaceuticals Holdings, Inc.
(CRBP) is the more profitable company, earning 0. 0% net margin versus -87. 7% for Innovation Beverage Group Limited — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRBP leads at 0. 0% versus -88. 2% for IBG. At the gross margin level — before operating expenses — IBG leads at 20. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — IBG or CRBP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is IBG or CRBP better for a retirement portfolio?
For long-horizon retirement investors, Innovation Beverage Group Limited (IBG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
13)). Both have compounded well over 10 years (IBG: -98. 8%, CRBP: -85. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between IBG and CRBP?
These companies operate in different sectors (IBG (Consumer Defensive) and CRBP (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.